Journal of Nutritional Science and Vitaminology · 2018 · 52 citations · 26 references
Life SciencesBiochemistryEndocrinologyCell SignalingMetabolic RegulationSignal TransductionCarbohydrate MetabolismDiabetes ControlDiabetes MellitusDiabetes Mellitus BiochemistryGlycemic ControlIncretin-based TherapiesAntidiabetic ActivityBasal SecretionBlood Glucose RegulationGlucagon-like Peptide 1 SignalingGlucagon-like PeptidesGlucose ConcentrationImpaired Glucose ToleranceSkeletal Muscle Physiology
Blackcurrants are berries that contain high levels of anthocyanins, particularly delphinidin 3-rutinoside (D3R). Several studies have reported that the consumption of blackcurrant extract (BCE) lowers blood glucose levels and ameliorates glucose tolerance, but the mechanism underlying this effect remains unclear. Glucagon-like peptide-1 (GLP-1) and AMP-activated protein kinase (AMPK) are considered one of the most significant molecular targets for the prevention and treatment of type 2 diabetes. In this study, we showed that dietary BCE significantly reduced blood glucose concentration and improved glucose tolerance in type 2 diabetic mice (KK-Ay). The basal GLP-1 concentration in plasma was significantly increased in the BCE group accompanied by upregulation of prohormone convertase 1/3 (PC1/3), the enzyme that processes intestinal proglucagon. Moreover, the level of phospho-AMPKα protein in skeletal muscle was significantly increased in the BCE group, and this was increase accompanied by significant upregulation of glucose transporter 4 (Glut4) proteins in the plasma membrane of BCE group. In conclusion, dietary BCE significantly reduced blood glucose concentration and improved glucose tolerance in association with increased basal GLP-1 concentration in plasma, upregulation of PC1/3 expression, and translocation of Glut4 to the plasma membrane of skeletal muscle in type 2 diabetic mice; furthermore, these effects were accompanied by activation of AMPK. Our findings demonstrated that D3R-rich BCE may help prevent diabetes and allow the dosages of diabetes drugs to be reduced.
26
Philip G. Reeves, Forrest H. Nielsen, G. C. Fahey · Journal of Nutrition · 1993 · 8.7K citations
GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN
Bernhard Kreymann, Mohammad A. Ghatei, Gareth Williams et al. · The Lancet · 1987 · 1.9K citations
Svetlana Mojsov, Gordon C. Weir, Joel F. Habener · Journal of Clinical Investigation · 1987 · 871 citations · Full text